孕早期接触司美格鲁肽后的妊娠结局。
Pregnancy outcomes following first trimester exposure to semaglutide.
作者信息
Morton Adam, He Jinwen
机构信息
Obstetric Medicine and Endocrinology, Mater Health, Raymond Terrace, South Brisbane, QLD, Australia.
Department of Medicine, University of Queensland, Herston, Brisbane, QLD, Australia.
出版信息
Obstet Med. 2025 Jun 4:1753495X251346330. doi: 10.1177/1753495X251346330.
BACKGROUND AND OBJECTIVE
To review pregnancy outcomes in women exposed to semaglutide during early pregnancy.
METHODS
A retrospective review of an obstetric database at a tertiary obstetric hospital in Brisbane, Australia.
RESULTS
Thirteen women were exposed to semaglutide in first trimester. One infant had significant cardiac anomalies in the setting of very poor maternal glycaemic control in first trimester, as well as maternal obesity and hypertension.
CONCLUSION
This study adds to the growing literature suggesting there is no increased risk of major congenital anomalies following first trimester exposure to semaglutide, however, until larger studies are available to confirm these findings, reproductive-age women using semaglutide should practice effective contraceptive methods. Preconception counselling of all women with diabetes mellitus is critical to avoid adverse pregnancy outcomes.
背景与目的
回顾孕早期暴露于司美格鲁肽的女性的妊娠结局。
方法
对澳大利亚布里斯班一家三级产科医院的产科数据库进行回顾性分析。
结果
13名女性在孕早期暴露于司美格鲁肽。1例婴儿出现严重心脏畸形，其母亲在孕早期血糖控制极差，同时伴有肥胖和高血压。
结论
本研究进一步丰富了现有文献，提示孕早期暴露于司美格鲁肽后，重大先天性畸形的风险并未增加。然而，在有更大规模研究证实这些发现之前，使用司美格鲁肽的育龄女性应采取有效的避孕措施。对所有糖尿病女性进行孕前咨询对于避免不良妊娠结局至关重要。
Zotero 插件